IgA pemphigus: the first two Scandinavian cases.

IgA pemphigus is a rare neutrophilic acantholytic skin disorder with only approximately 70 cases reported in the indexed literature to date. Here we describe two patients with IgA pemphigus (subcorneal pustular dermatosis type and intraepithelial neutrophilic type) that to our knowledge are the first Scandinavian patients with this disease. Initially, both patients were misdiagnosed as subcorneal pustular dermatosis of Sneddon and Wilkinson and only subsequent careful immunofluorescence studies (in one case with confocal laser scanning microscopy) led to the correct diagnosis. Apart from the expected IgA depositions on epidermal cell surfaces, both patients demonstrated some degree of intercellular IgG-specific immunofluorescence. No circulating IgA autoantibodies were detected. One patient was treated with the standard regime comprising dapsone and prednisolone, whereas in the other case a novel methotrexate and prednisolone combination treatment showed marked clinical efficacy.
AuthorsRobert Gniadecki, Anette Bygum, Ole Clemmensen, Else Svejgaard, Susanne Ullman
JournalActa dermato-venereologica (Acta Derm Venereol) Vol. 82 Issue 6 Pg. 441-5 ( 2002) ISSN: 0001-5555 [Print] Norway
PMID12575851 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Anti-Inflammatory Agents
  • Dermatologic Agents
  • Immunoglobulin A
  • Dapsone
  • Prednisolone
  • Methotrexate
  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents (therapeutic use)
  • Blister (drug therapy, immunology)
  • Dapsone (therapeutic use)
  • Dermatologic Agents (therapeutic use)
  • Diagnosis, Differential
  • Drug Therapy, Combination
  • Fluorescent Antibody Technique, Direct
  • Humans
  • Immunoglobulin A (analysis)
  • Male
  • Methotrexate (therapeutic use)
  • Microscopy, Confocal
  • Middle Aged
  • Pemphigus (drug therapy, immunology, pathology)
  • Prednisolone (therapeutic use)
  • Scandinavian and Nordic Countries
  • Skin (immunology, pathology)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: